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Background and Objectives. The transplantation of
mobilized peripheral progenitor cells has resulted in
shortening of neutrophil and platelet engraftment
times following high-dose chemotherapy. Since  retic-
ulated platelet percentage (RP%) has been estab-
lished as a measure of bone marrow platelet pro-
duction, we performed this type of analysis on the
thrombopoietic compartment during transplant-relat-
ed chemotherapy.
Design and Methods. Kinetics of thrombopoiesis of
19 patients with solid tumors undergoing a single or
double autologous peripheral blood progenitor cell
transplant was characterized by evaluating the level
of RP. The correlation between CD34+ cell subsets
and the time of highest percentage of RP was also
evaluated.
Results. The percentage of RP increased from day +8
after single transplant reaching the peak (3.4%) at
day +10. In the group of patients receiving double
transplant, the peak RP value of observed after the
second transplant is not significantly different from
that observed after the first transplant (3 vs 3.7%).
In a subgroup of patients both the number of CD34+
cells/Kg infused and the percentage of CD34+ CD61+
cell subsets correlated with the day of RP peak.
Interpretation and Conclusions. These results sug-
gest that RP measurement is an early indicator of
engraftment. Additionally, the observation that RP
percentage is high at the time of platelet transfusion
in 13 out of 20 cases of transfusions (the 7 cases
with low RP value being transfused during the period
of obligate thrombocytopenia) suggests that the eval-
uation of this parameter, together with the platelet
count, can be used to monitor the need for platelet
transfusion.
©2001, Ferrata Storti Foundation
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High dose chemotherapy with autologoushematopoietic stem cell support has beenshown to be a feasible and safe treatment
modality for a variety of malignant diseases.
Hematologic recovery is more rapid after infusion
of peripheral blood stem cells than after bone mar-
row derived stem cells, with a significant shorten-
ing of the period of both neutropenia and throm-
bocytopenia.1,2 One major clinical problem in
autologous stem cell transplantation is the risk of
late platelet engraftment which is seen in 10-20%
of patients transplanted,3,4 therefore the kinetics of
bone marrow recovery with respect to platelet pro-
duction must be investigated. Moreover, clinical
tests of platelet homeostasis, such as the platelet
count, have not consistently demonstrated utility
in predicting platelet engraftment. The determi-
nation of the percentage of reticulated platelets
(RP) in peripheral blood may provide a measure of
thrombopoiesis,5-8 similar to the use of erythrocyte
reticulocyte count, to evaluate  erythropoiesis.5
We, therefore, optimized the methodology for
quantifying reticulated platelets using the RNA
fluorochrome, thiazole orange (TO), in order to
evaluate the patterns of platelet recovery follow-
ing high dose chemotherapy and autologous stem
cell support in patients with solid tumors. Finally
the correlation between CD34+ lineage-specific
cell subset numbers in a subgroup of patients and




We studied 19 patients (18 with metastatic
breast cancer (MBC), 1 with Ewing’s sarcoma)
receiving high dose chemotherapy with autologous
peripheral blood progenitor cell transplant (PBPCT).
Nine out of 18 patients with MBC received a sec-
ond PBPCT. Performance status was 0 (0-1). No
patient had positive bone marrow cytology. The
median age of patients was 40 years (range 28-55).
The conditioning regimen included thiotepa (600
mg/m2)+L-PAM (160 mg/m2) and, in 9 patients who
received a second PBPCT, idarubicin (60 mg/m2, 48
hours in infusion). Patients with a platelet count
<20×109/L received platelet transfusion.
The day of PBSC infusion was designated as day
0. Platelet counts were monitored from day 0, while
RP was assessed from day +5 to day +13 because
an obligate period (8-9 days) of thrombocytopenia
is reported.8 Thirty-five healthy subjects of the
same age with no history of a coagulation defect
formed the control group.
Mobilization and stem cell collection 
All patients received more than one regimen of
cytotoxic chemotherapy. PBPC were collected after
a standard dose chemotherapy including granulo-
cyte colony-stimulating factor (G-CSF) until leuka-
pheresis was completed. Leukapheresis was per-
formed when blood levels of CD34+ cells exceeded
20×103/mL blood. In each leukapheresis product
the number of CD34+ cells was enumerated before
freezing, in accordance with previously described
recommendations.9,10
Estimation of CD34+ subsets
The identification of CD34+ cells was based on
the Milan protocol.11 Briefly, CD34+ cells were
stained with class III anti-CD34 PE-conjugated
(Immunotech, Marseille, France). Mouse IgG1 PE
isotype control (Immunotech, Marseille, France)
was included for determination of background
staining. The positive population (SSC/FL-2) was
identified in the upper left quadrant, among cells
with a side scatter profile as lymphocytic cells.12,13
The negative control was subtracted if it exceeded
0.05%. The analysis should consider not only the
percentage of positive cells but also the type of
antigen expression. This evaluation was performed
on a minimum of 1,000 cells acquired in a CD34
SSC/FL gate. We double-stained the cells with anti-
CD34 PE conjugated monoclonal antibody (moAb)
plus one of the following conjugated moAbs: anti-
CD38 FITC (Immunotech); anti-CD117 FITC (Caltag
Laboratories, San Francisco, CA, USA); anti-HLA-
DR FITC (Exalpha Corporation, Boston, USA); anti-
CD33 FITC (Serotec, Oxford, England) and anti-
CD61 FITC (Exalpha Corporation, Boston, USA).
Mouse Ig isotype controls were included for each
moAb.
Evaluation of reticulated platelets
Venous blood was collected into a tube contain-
ing ethylenediamine tetra-acetic acid (EDTA) and
gently inverted to mix the blood and anticoagulant.
A platelet count was measured by an automated
analyzer (STK-S Coulter, Miami, FL, USA). Platelets
were prepared as previously described by Ault et al.5
Platelet-rich plasma was prepared by centrifuga-
tion at 120 g for 10 min. The platelets were fixed
in 1% paraformaldehyde for at least 2 hours,
washed twice and resuspended at 50×109/L in PBS
containing 2 mM/L EDTA (pH 7.2). Subsequently,
100µL of this suspension were incubated with 1 mL
of the thiazole orange (TO, final concentration 90%
vol/vol) (Retic-COUNT, Becton Dickinson, San José,
CA, USA) at room temperature in the dark for 1 hour.
Platelets were identified by a Coulter Epics XL flow
cytometer (Coulter Corporation) on the basis of
their characteristic size (log forward scatter) and
granularity (log side scatter) and an electronic gate
was drawn around the platelet cloud to exclude all
non-platelet particles.14 Ten thousand platelet
events were collected. It has been recently shown
that a large proportion of the TO signal of platelet
is RNase insensitive and derives from other platelet
compartments, such as mitochondrial DNA or
dense granule nucleotides.15,16 Therefore the TO flu-
orescence histogram of these gated events was
analyzed by a linear gate set to capture approxi-
mately 1% of the reticulated platelet controls.
When a single such marker was used to analyze a
series of 35 normal samples in order to determine
the variability of the technique, the average per-
cent reticulated platelets was 0.42% (± 0.18 s.d.
observed range, 0.2 to 1.0%). This standard gate
was used to analyze data from all samples and
measure the percentage of TO+ events in this gate.6
A normal control sample was prepared at the same
time as each patient sample and run with the
patient samples in order to identify possible day-
to-day variability. The inter-assay CV evaluated in
one patient was 8.6% and the intra-assay CV was
2.7%.
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Statistical analysis
The results are expressed as the median. Com-
parisons among the groups were evaluated by Stu-
dent's t-test. Any p value <0.05 was considered
statistically significant. A linear regression analy-




In the control group, composed of 35 healthy
individuals, the median RP percentage was 0.4%
(range 0.2-1%). Kinetics of RP was evaluated in
twenty-eight courses of high dose chemotherapy.
In 10 patients receiving single PBPCT, the median
platelet count nadir was 12.35×109/L (range 5.1-
17.3×109/L) and occurred at median day +7 (range
5-9). The median time to platelet recovery
(>20×109/L) was day +11 (range 10-13). The behav-
ior of the platelet count is reported in Figure 1. 
The median RP percentage increased (1.65%;
range: 1.1-3.1) on day +8 (range 5-9) reaching the
median peak value (3.4%; range: 1.7-10.4) on day
+10 (range 9-12), as shown in Figure 1. Eight
patients required platelet support; platelet trans-
fusions were given when the median platelet count
and median RP percentage were 14×109/L (range
5.1-17.3×109/L) and 1.2% (range 0.4-3.1), respec-
tively. In five out of these patients the RP percent-
age was >1%. Nine patients received a double
course of high dose chemotherapy with BCS. After
the first transplant, the median platelet count nadir
was 16×109/L (range 7.1-17×109/L) and occurred at
median day +7 (range 6-9) (Figure 2). The same
median value of platelet count nadir range (9.1-
18×109/L) was observed after the second trans-
plant at median day +7.5 (range 7-10) (Figure 2).
The median time to platelet recovery was 11 days
(range 10-13) after the first transplant and 10 days
(range 9-12) after the second one. After the first
transplant the median RP percentage increased to
1.3% (range: 1.1-1.9) at median day +8 (range 5-
10). The median peak value of RP occurred on day
+11 (range 10-12) with a RP percentage of 3.7%
(range 1.7-6.9) (Figure 2). After the second trans-
plant the median RP percentage started to increase
on day +9 (range 8-9) with a value of 1.45% (range
1.1-2.4). The median peak RP value was reached on
day +11 (range 8-12) with a median percentage of
3% (range 2.2-9.5). The difference between the
peaks of RP percentage observed after the first and
second transplant was not statistically significant
(p>0.05) (Figure 2).
After the first transplant 7 patients required
platelet support when the median RP percentage
was 1.1% (range: 0.3-1.9); in 4 out of these
patients RP percentage was ≥1.1%. After the sec-
ond transplant 5 patients required platelet support
and presented a median RP percentage of 1.4%
(range: 0.4-2.2); in 4 out of these patients RP per-
centage was ≥1.2%. All the other patients trans-
fused were in the period of obligate thrombocy-
topenia.
Figure 1. Median daily reticulated platelet percentage 
plotted against platelet count in 10 patients undergoing
single PBPCT.  RP % median;  platelet count.
Figure 2. Median daily reticulated platelet percentage and
platelet count in 9 patients undergoing double PBPCT.
First PBPCT:  RP % median;  platelet count. Second
PBPCT:  RP % median;  platelet count.
Correlation between RP and CD34+ cell
subsets
Patients undergoing a single transplant received
a median of 7.01×106 CD34+ cells/kg (range 2.24-
9.7), which was not significantly different from the
dose infused to the patients receiving a double
transplant: 5.98×106 (range: 2.5-8.9) and 6.4×106
(range: 2.5-9.2) in the first and second transplant,
respectively. The number of CD34+ cells/kg rein-
fused correlated with the day of RP peak 
(r= -0.4353; p=0.02) (Figure 3). 
Cytofluorimetric analysis of CD34+ cell subpop-
ulations was performed in 6 patients: the results,
expressed as median percentages, are shown in
Table 1. The median percentage of uncommitted
(CD34+CD38-) was 44.75%. More than 90% of
CD34+ cells co-expressed early antigens such as
CD117 and HLA-DR, whereas lineage-specific anti-
gens CD33 and CD61 were expressed in 23% and
14% of CD34+ cells, respectively.
The percentage of the CD34+CD61+ cells corre-
lated with the day of RP peak. The analysis showed
an inverse correlation between the percentage of
CD34+CD61+ cells and the day of highest percent-
age of RP (r= -0.8248; p= 0.0434). No other sub-
set of CD34+ cells defined by the expression of the
above described lineage antigens correlated with
the day of peak RP value.
Discussion
The prolonged thrombocytopenia caused by
delayed platelet engraftment represents one of
major clinical problems in PBSC transplantation.
Many factors can be involved, including severe
post-transplant regimen-related toxicity or inade-
quate quantity of transplanted stem cells. Togeth-
er with platelet count the mean platelet volume
(MPV)  represents an available parameter to eval-
uate the rate of platelet production.17 It is normal
or decreased in patients with reduced platet pro-
duction,18 increased when megathrombocytes
appear or young platelets rise in the peripheral
blood.19 Furthermore, even if an increase of MPV
can indicate accelerated thrombocyte production,
platelet volume is not related to aging.20,21 Addi-
tonally, many variables such as the modality of
blood taking, temperature, interval between time
of drawing blood and time of performing assays
and finally the role of anticoagulants can influence
the mean platelet volume measurement,17,22 thus
obliging careful interpretation of the results.23
The mean values of MPV observed in our patients
increased compared to those of normal subjects
with a peak on day +10 post-tranplant (data not
shown). The increase was not linear and was not
observed in all patients tested (data not shown).
Reticulated platelet count has recently been
introduced as a more important parameter for
accurate measurement of the rate and kinetics of
thrombopoiesis.24 In the present study we mea-
sured the level of RP in order to evaluate the kinet-
ics of thrombopoiesis in patients with solid tumors
receiving high dose chemotherapy with single or
double autologous PBPCT. We demonstrate that
the rise in the RP percentage, which reflects mega-
karyocyte engraftment, can anticipate the initial
rise of platelet count. As the platelet count rises,
the percentage of RP falls, according to previous
reports.7,8,25
It is interesting to observe that the patterns of
RP release during autologous bone marrow trans-
plant (ABMT) and PBPCT are different. The peak RP
percentage is higher after PBPCT than after ABMT;
this difference may reflect a more homogenous
population of platelet precursors harvested by the
PBPC technique, which has a greater synchrony of
maturation.7
Furthermore, the fact that the peak RP percent-
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Figure 3. Correlation between the number of CD34+
cells × 106/Kg infused and day of RP peak.
Table 1. Median percentage and range of CD34+ cell 
subsets in 6 patients.






age after a second transplant is not significantly
different from that observed after a first transplant
demonstrates that thrombopoietic capacity is
retained despite an additional course of high dose
chemotherapy.26
It has been demonstrated that the total number
of CD34+ cells/kg infused at transplant is the most
important factor influencing the time of platelet
recovery.13 The present study shows a significant
correlation between the number of CD34+ cells
infused and the day of peak RP percentage. 
CD38 antigen is expressed on more differentiat-
ed cells and is not present on primitive progenitors
that, on the contrary, show CD117 and HLA-DR
antigens. High numbers of CD34+CD38- cells in the
reinfused stem cell product are associated with
better long-term hematopoiesis.13 In the present
work we demonstrate a significant correlation
between CD34+CD61+ cell subsets and the time of
peak RP percentage. Thus, a small but significant
population of CD34+ expressing megakaryocyte lin-
eage-associated cell surface antigens, giving rise to
regeneration of megakaryopoiesis after transplan-
tation, can be detected.27 No other lineage-specif-
ic CD34+ cell subsets correlated with the time to
platelet engraftment.
In conclusion, we demonstrate that the level of
RP is an early indicator of engraftment after trans-
plantation of mobilized peripheral blood progeni-
tor cells, as previously suggested.7,8,26 The observa-
tion that RP percentage is high at the time of
platelet transfusion in 13 out of 20 cases of trans-
fusions (the 7 patients with low RP percentage
being transfused during the period of obligate
thrombocytopenia) suggests that the evaluation of
this parameter, together with platelet count, can be
used to monitor the need for platelet transfusions
in patients undergoing high dose chemotherapy.
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Potential implications for clinical practice
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